The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
July 11th 2025
States have expanded access to over-the-counter ivermectin, raising concerns among health experts about safety, misinformation, and self-medication risks.
Independent Pharmacists: Separate Yourself From the Competition
October 7th 2018Offering immunizations (and making sure to carefully assess immunizations are up to date), medication therapy management (MTM), medication synchrnonization, and point of care testing are all ways, Kneeland explained, that pharmacists can carve out a niche for themselves.
Read More
Pharmacy Times and Parata Systems Celebrate 2018 Next-Generation Pharmacist Winners
October 7th 2018Pharmacy Times® and Parata Systems named the winners of the 2018 Next-Generation Pharmacist® Awards yesterday at a ceremony held concurrently with the 2018 NCPA Annual Meeting in Boston, Massachusetts.
Read More
FDA Approves Second Drug Treatment for Polyneuropathy
October 6th 2018The FDA has approved Akcea Therapeutics' inotersen (Tegsedi), an antisense oligonucleotide that inhibits the production of the transthyretin protein (amyloid), for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Read More
Officials with NCPA Applaud Opioid Relief Package, Which President Expected to Sign
October 6th 2018HR 6—which was passed in the Senate on Wednesday and in the House of Representatives last week—instructs the Secretary of Health and Human Services to establish a technical expert panel to review quality measures regarding opioids and opioid use disorders.
Read More
FDA Approves Prophylactic Treatment for Individuals With Hemophilia A
October 4th 2018Officials with the FDA have approved emicizumab-kxwh (Hemlibra, Genentech) for routine prophylaxis to prevent or reduce frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors.
Read More
FDA Approves Antibacterial Treatment for Lung Disease Through Novel Pathway
September 29th 2018The FDA has approved amikacin liposome inhalation suspension (Arikayce, Insmed), for the treatment of lung disease caused by a group of bacteria in a limited population of patients with the disease who do not respond to conventional treatment.
Read More
FDA Approves First Treatment for Advanced Cutaneous Squamous Cell Carcinoma
September 29th 2018Officials with the FDA have approved cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or radiation.
Read More